Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Rusfertide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Protagonist Reports Long Term Rusfertide Results At EHA2024 Congress
    Protagonist Reports Long Term Rusfertide Results At EHA2024 Congress

    14 Jun 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=877298&lang=en

    ACCESSWIRE
    14 Jun 2024
    Share Share
    Protagonist Presents Rusfertide Phase 2 REVIVE OLE Data At EHA 2024
    Protagonist Presents Rusfertide Phase 2 REVIVE OLE Data At EHA 2024

    14 May 2024

    // ACCESSWIRE

    https://www.accesswire.com/863148/protagonist-therapeutics-announces-oral-presentation-on-long-term-follow-up-of-rusfertide-phase-2-revive-study-open-label-extension-at-the-european-hematology-association-2024-congress

    ACCESSWIRE
    14 May 2024
    Share Share
    Protagonist Announces Closing of Worldwide Rusfertide License
    Protagonist Announces Closing of Worldwide Rusfertide License

    18 Mar 2024

    // ACCESSWIRE

    https://www.accesswire.com/843636/protagonist-therapeutics-announces-closing-of-worldwide-rusfertide-license-and-collaboration-agreement-with-takeda

    ACCESSWIRE
    18 Mar 2024
    Share Share
    New England Journal of Medicine Publishes Results of Positive Ph 2 of Rusfertide
    New England Journal of Medicine Publishes Results of Positive Ph 2 of Rusfertide

    21 Feb 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=835611&lang=en

    ACCESSWIRE
    21 Feb 2024
    Share Share
    Takeda and Protagonist Therapeutics, Inc. Enter into Agreement for Rusfertide
    Takeda and Protagonist Therapeutics, Inc. Enter into Agreement for Rusfertide

    31 Jan 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=829846&lang=en

    ACCESSWIRE
    31 Jan 2024
    Share Share
    Protagonist Announces Results from REVIVE Study of Rusfertide
    Protagonist Announces Results from REVIVE Study of Rusfertide

    15 Mar 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=743817&lang=en

    ACCESSWIRE
    15 Mar 2023
    Share Share